Autopsy report · NCT01605370

Can Nebivolol Reverse Inappropriate Left Ventricular Mass in Hypertensive Patients?

“Difficulty in identifying subjects satisfying the inclusion criteria.”

The sponsor’s own words in the registry.

Life of this trial

• Ran for about 9 months before it stopped.
• 1 participant enrolled.
• Results were posted on the registry 1 year 2 months after it ended.

Vital statistics

Status

Terminated

Phase

Phase 4

Sponsor

Mayo Clinic

Sponsor type

University, hospital or other

Conditions

Hypertension

Interventions

Nebivolol; Metoprolol succinate

Participants

1

Sites

1

Countries

United States

Trials that died the same way

• Environmental Influence on Gambling Behavior
  “difficulties of inclusion of subjects” (83% match in meaning)
• Impact of Sleep Apnea on Diabetic Foot Wound.
  “Difficulty including subjects corresponding to the criteria.” (79% match in meaning)
• Thalidomide Versus Infliximab in New Onset Crohn's Disease With Poor Prognostic Factors
  “Difficulty in recruiting subjects who meet the inclusion/exclusion criteria” (77% match in meaning)
• Insulin Resistance in Pulmonary Arterial Hypertension
  “difficulty in finding eligible subjects” (76% match in meaning)
• Evaluation of Dextenza in Patients With Ocular GVHD and Effects on Ocular Surface Disease Outcomes
  “Due to difficulty enrolling subjects whom had not meet the inclusion criteria” (73% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.